The Food and Drug Administration (FDA) has updated the risk evaluation and mitigation strategy (REMS) labeling for Filspari ® (sparsentan) to decrease the frequency of liver function monitoring and ...

FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has approved updated Risk Evaluation and Mitigation Strategy (REMS) labeling for FILSPARI® ...

"Today’s approval of streamlined monitoring requirements reflects the strong safety profile of FILSPARI established to date across clinical and real-world use, simplifying access for patients," said ...

Travere Therapeutics (TVTX) presented new data further demonstrating the clinical benefit of FILSPARI in IgA nephropathy and reinforcing its potential in focal segmental glomerulosclerosis at the ...

Travere recently received accelerated approval for Filspari (sparsentan) for the treatment of IgA Nephropathy. See why I downgrade TVTX stock to a hold.

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Travere Therapeutics' (NASDAQ:TVTX) oral medicine Filspari (sparsentan) to reduce proteinuria in adults with primary ...

sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare ...

(RTTNews) - Travere Therapeutics Inc. (TVTX) said that the U.S. Food and Drug Administration granted accelerated approval to Filspari (sparsentan) to reduce proteinuria in adults with primary IgA ...

(RTTNews) - Travere Therapeutics Inc. (TVTX) announced that new data further demonstrates the clinical benefit of FILSPARI (sparsentan) in IgA nephropathy (IgAN) and reinforces its potential in ...

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress Data from SPARTACUS and PROTECT OLE to show significant proteinuria reduction when replacing RASi with ...

Filspari, which was approved under the FDA’s accelerated approvals pathway in February 2023 for primary IgAN patients who are at risk of rapid disease progression, is an oral, once-daily ...